Stock (Symbol) | Stock Price | |
Celgene (CELG) |
$76 |
|
Data is as of | Expected to Report | Sector |
November 12, 2012 |
Jan 21 |
Healthcare |
Sharek’s Take | ||
Celgene continues to be one of the stock market’s most under appreciated stocks. CELG grew profits 26% last quarter — the slowest growth in more than a year — yet the stock is sitting with a P/E of only 15. The company’s got a full pipeline of drugs its developing, and has an estimated Long Term Growth Rate of 23%. This is a growth stock but with enough safety for conservative investors. | ||
Ten-Year Chart | ||
CELG started to make its big move in March of 2005. This was a hard one to get into because the stock was $13-$17 that month and the company only made $0.18 that year. Investors looked ahead to 2006 when they got in. Since the stock went from $15 to $66 (Oct 07), it needed time to base and digest gains. Now CELG is undervalued and ready for another run. | ||
Profit History | ||
Here in the Profit History we see CELG had a HUGE P/E from 2003-2006. Then the stock based and the P/E fell even though profits kept climbing. Now I feel CELG is worth 20 times earnings, this stock has solid upside through 2014. | ||
Power Ranking | Bottom Line | |
Conservative Portfolio
3 of 18 |
Celgene is a combination of a growth stock and a conservative stock, and is a perfect addition to most any portfolio. CELG has solid profit growth, a low P/E and the stock’s been moving higher. Celgene is ranked #3 overall in the Conservative Growth Portfolio Power Rankings. |